16.75
Overview
News
Price History
Option Chain
Financials
Why BAX Down?
Discussions
Forecast
Stock Split
Dividend History
Baxter International Inc stock is traded at $16.75, with a volume of 7.62M.
It is up +0.78% in the last 24 hours and up +0.42% over the past month.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
See More
Previous Close:
$16.62
Open:
$16.74
24h Volume:
7.62M
Relative Volume:
0.79
Market Cap:
$8.65B
Revenue:
$11.32B
Net Income/Loss:
$-981.00M
P/E Ratio:
-8.5757
EPS:
-1.9532
Net Cash Flow:
$714.00M
1W Performance:
-6.63%
1M Performance:
+0.42%
6M Performance:
-6.69%
1Y Performance:
-44.96%
Baxter International Inc Stock (BAX) Company Profile
Name
Baxter International Inc
Sector
Industry
Phone
(224) 948-2000
Address
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BAX
Baxter International Inc
|
16.75 | 8.58B | 11.32B | -981.00M | 714.00M | -1.9532 |
|
ISRG
Intuitive Surgical Inc
|
451.38 | 160.21B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
BDX
Becton Dickinson Co
|
144.17 | 41.62B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
MDLN
Medline Inc
|
45.32 | 37.37B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
ALC
Alcon Inc
|
74.45 | 35.82B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
RMD
Resmed Inc
|
207.88 | 30.38B | 5.40B | 1.49B | 1.78B | 10.12 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Downgrade | Argus | Buy → Hold |
| Aug-04-25 | Downgrade | Stifel | Buy → Hold |
| Aug-01-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-26-25 | Resumed | Goldman | Buy |
| Feb-24-25 | Upgrade | Argus | Hold → Buy |
| Feb-20-25 | Resumed | Barclays | Overweight |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-30-24 | Initiated | Goldman | Neutral |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-03-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-15-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jun-24-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-18-22 | Reiterated | KeyBanc Capital Markets | Overweight |
| Feb-18-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-18-22 | Reiterated | Raymond James | Outperform |
| Feb-18-22 | Reiterated | Stifel | Buy |
| Feb-18-22 | Reiterated | UBS | Neutral |
| Feb-18-22 | Reiterated | Wells Fargo | Overweight |
| Feb-11-22 | Initiated | Goldman | Neutral |
| Jan-07-22 | Resumed | Citigroup | Buy |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-21 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-03-21 | Upgrade | Barclays | Equal Weight → Overweight |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-21 | Downgrade | UBS | Buy → Neutral |
| Dec-15-20 | Downgrade | Goldman | Buy → Neutral |
| Oct-01-20 | Upgrade | Citigroup | Neutral → Buy |
| Sep-04-20 | Downgrade | Argus | Buy → Hold |
| Jun-24-20 | Initiated | Oppenheimer | Outperform |
| Mar-19-20 | Upgrade | Stifel | Hold → Buy |
| Mar-18-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-02-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-26-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Apr-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-19 | Upgrade | Citigroup | Neutral → Buy |
| Jan-02-19 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Nov-02-18 | Upgrade | Argus | Hold → Buy |
| Oct-16-18 | Initiated | Barclays | Underweight |
| May-17-18 | Resumed | Piper Jaffray | Overweight |
| Feb-06-18 | Reiterated | Citigroup | Neutral |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
View All
Baxter International Inc Stock (BAX) Latest News
Pheochromocytoma Market to Reach USD 3.86 Billion by 2033 at 8.5% - openPR.com
Baxter International Stock Outlook: Is Wall Street Bullish or Bearish? - Barchart
Baxter International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Research Alert: CFRA Keeps Hold Rating On Shares Of Baxter International Inc. - Moomoo
Assessing Baxter International (BAX) Valuation After Earnings Beat And Reaffirmed Outlook - Yahoo Finance
Baxter International Inc. (NYSE:BAX) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
Baxter International (BAX) Is Down 5.2% After Q1 Loss But Turnaround Guidance ReaffirmedWhat's Changed - Yahoo Finance UK
Baxter Profit Plunges 35% As Tariffs, Costs Bite - Sahm
Baxter International (NYSE:BAX) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat
Baxter International (NYSE:BAX) Given New $19.00 Price Target at Stifel Nicolaus - MarketBeat
Baxter International (NYSE:BAX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Baxter International Inc. Q1 2026 Financial Results: Revenue, Earnings, and Key Financial Statements - Minichart
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Baxter International Inc. (NYSE:BAX) to Issue Quarterly Dividend of $0.01 - MarketBeat
Barclays Adjusts Baxter International Price Target to $27 From $25 - marketscreener.com
Goldman Sachs Adjusts Baxter International Price Target to $19 From $17 - marketscreener.com
TD Cowen Adjusts Baxter International Price Target to $20 From $22 - marketscreener.com
MSN Money - MSN
Baxter International Inc. (NYSE:BAX) Q1 2026 Earnings Call Transcript - Insider Monkey
What's Going On With Baxter International Stock Friday?Baxter International (NYSE:BAX) - Benzinga
Goldman Sachs Maintains Baxter International Inc(BAX.US) With Hold Rating, Cuts Target Price to $19 - Moomoo
Baxter International Inc (BAX) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives - GuruFocus
Baxter International (BAX) Q4 EPS Loss Deepens And Tests Bullish Margin Recovery Narrative - simplywall.st
Baxter International (NYSE:BAX) Releases Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Baxter International Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:BAX) 2026-04-30 - Seeking Alpha
Baxter International’s Earnings Call Signals Cautious Turnaround - TipRanks
Baxter beats quarterly estimates, monitors effect from Middle East conflict - marketscreener.com
Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating - Insider Monkey
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter International Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Special items push Baxter (NYSE: BAX) to small Q1 2026 net loss - Stock Titan
Baxter International Reports Q1 2026 Results: Sales Rise 3% to $2.7B, Adjusted EPS at $0.36, Reiterates Full-Year Outlook - Minichart
Baxter International Stock Jumps After Earnings Beat, But Novum Pump Risk Still Hangs Over 2026 - TechStock²
Baxter International Releases Q1 2026 Financial Results - AlphaStreet
Baxter beats quarterly expectations on strong demand for medical devices - marketscreener.com
Baxter Stock Forecast What Is Driving Momentum - Kalkine Media
Baxter (BAX) Reports Strong Q1 2026 Earnings, Shares Rise - GuruFocus
Baxter stumbles — but beats expectations — as turnaround takes hold - Crain's Chicago Business
Baxter Q1 2026 slides: earnings beat amid margin pressure, turnaround continues - Investing.com India
Baxter (BAX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Earnings call transcript: Baxter Q1 2026 beats earnings, stock rises - Investing.com
Transcript : Baxter International Inc., Q1 2026 Earnings Call, Apr 30, 2026 - marketscreener.com
Earnings call transcript: Baxter Q1 2026 beats earnings, stock rises By Investing.com - Investing.com Canada
Baxter Gains Strength Amid S&P 500 Index Healthcare Momentum - Kalkine Media
Baxter International Q1 Adjusted Earnings Fall, Revenue Rises; 2026 Adjusted Earnings Outlook Reaffirmed - marketscreener.com
Baxter International Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Baxter stock rises as overseas sales drive Q1 beat (BAX:NYSE) - Seeking Alpha
Baxter Posts Q1 Loss Amid Mixed Sales Performance - TipRanks
Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Baxter International Inc. (NYSE:BAX) Beats Q1 Estimates Amid Tariff Headwinds and Pump Woes - ChartMill
Baxter International Inc Stock (BAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):